Concert Pharmaceuticals, Inc.

99 Hayden Avenue, Suite 500

Lexington, MA  02421

Tel: 781.860.0045


Leadership:
Roger Tung, Ph.D.
President & CEO


Website:
www.concertpharma.com


Information:
info@concertpharma.com

Concert Pharmaceuticals, Inc.

Flagship Partners:  Doug Cole
Initial Investment: 
2006
Status: 
Public

Concert Pharmaceuticals (NASDAQ: CNCE) is a publicly traded clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that can be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer.